Lefitolimod: Phase I started

Mologen said the University of Texas MD Anderson Cancer Center began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate lefitolimod once weekly plus 3 mg/kg IV Yervoy ipi...